164 completed, 39 recruiting, 35 terminated, 22 active not recruiting. 287 Phase 1, 70 Phase 2.
Follow Neuroblastoma: new trials by email Literature Review of Neuroblastoma trials Research Report on Neuroblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin) - Neuroblastoma (NBL), Ewing Sarcoma | Phase 1 | Not yet recruiting | Universität Münster | 30 | 2027-10-01 | 2026-11-03 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-11-03 |
| 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma GD2, PSMA and CD276 CAR-T cells - Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2026-12-31 | 2026-10-30 |
| B7-H3.CD28Z.CART in Solid Tumors B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide - Pediatric Solid Tumor, Neuroblastoma | Phase 1 | Recruiting | Robbie Majzner | 40 | 2026-08-24 | 2026-09-03 |
| NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-07-15 | 2026-07-21 |
| Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma Dinutuximab Beta, Induction chemotherapy - High Risk Neuroblastoma | Phase 1 | Recruiting | Chang Gung Memorial Hospital | 30 | 2026-07-01 | 2026-10-06 |
| Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors Becotatug Vedotin - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma | Phase 1 | Recruiting | Sun Yat-sen University | 51 | 2026-05-30 | 2026-05-13 |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas Eflornithine (DFMO), AMXT 1501 Dicaprate - Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes | Phase 1 / Phase 2 | Recruiting | Milton S. Hershey Medical Center | 265 | 2026-05-13 | 2026-09-03 |
| Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma Therapeutic Inducers of Natural Killer Killing (ThINKK) - Leukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid) | Phase 1 | Not yet recruiting | Michel Duval | 12 | 2026-05-01 | 2026-04-08 |
| Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma EB-DTNB-NK, Fludarabine, Cyclophosphamide - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-03-30 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells - Rhabdomyosarcoma, Ewing Sarcoma | Phase 1 | Recruiting | Children's National Research Institute | 18 | 2026-01-27 | 2026-08-13 |
| An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma anti-GD2-800CW - Neuroblastoma | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 22 | 2025-11-05 | 2026-02-10 |
| Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma rhIL-15, Dinituximab, Temozolomide - Neuroblastoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 40 | 2025-10-21 | 2026-10-21 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-08-19 | 2026-10-06 |
| Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma Naxitamab, Irinotecan, Temozolomide - Neuroblastoma, Neuroblastoma Recurrent | Phase 1 | Recruiting | Steven DuBois, MD | 18 | 2025-06-27 | 2026-07-14 |
| PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma PHOX2B PC-CAR T Cells - Refractory Neuroblastoma, Relapsed Neuroblastoma | Phase 1 | Active not recruiting | Stephan Grupp MD PhD | 38 | 2025-06-20 | 2026-07-01 |
| A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma autologous NK cell plus GD2 antibody - Neuroblastoma, GD2 Antibody | Phase 1 / Phase 2 | Not yet recruiting | Guangzhou Women and Children's Medical Center | 15 | 2025-05-01 | 2025-04-29 |
| PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors PEEL-224, Vincristine, Temozolomide (TMZ) - Refractory Solid Tumors, Relapsed Solid Tumors | Phase 1 / Phase 2 | Recruiting | Theodore Laetsch | 59 | 2025-03-23 | 2026-10-06 |
Showing 20 of 287. Sign in to see all of them.
Osteosarcoma (69) · Sarcoma (56) · Rhabdomyosarcoma (52) · Wilms Tumor (51) · Sarcoma, Ewing (47) · Medulloblastoma (41) · Neoplasms (41) · Recurrence (39) · Esthesioneuroblastoma, Olfactory (29) · Neuroectodermal Tumors, Primitive, Peripheral (27) · Lymphoma (26) · Astrocytoma (25) · Brain Neoplasms (25) · Breast Neoplasms (25)
Neoplasms by Histologic Type (287) · Neoplasms, Glandular and Epithelial (287) · Neoplasms, Nerve Tissue (286) · Neoplasms, Neuroepithelial (286) · Neuroectodermal Tumors (286) · Neuroectodermal Tumors, Primitive (279) · Neoplasms, Germ Cell and Embryonal (276) · Neuroectodermal Tumors, Primitive, Peripheral (260) · Neoplasms (246) · Neoplasms by Site (123) · Neoplasms, Connective and Soft Tissue (118) · Neoplasms, Connective Tissue (91) · Neoplasms, Bone Tissue (85) · Nervous System Diseases (82) · Urogenital Diseases (78)
Cyclophosphamide (38) · Filgrastim (23) · Irinotecan (23) · Temozolomide (22) · Topotecan (16) · Melphalan (14) · Peripheral Blood Stem Cell Transplantation (14) · Vincristine (14) · Etoposide (13) · Granulocyte Colony-Stimulating Factor (13) · dinutuximab (13) · fludarabine (13) · Carboplatin (12) · Interleukin-2 (12) · Isotretinoin (11)
National Cancer Institute (NCI) (42) · Memorial Sloan Kettering Cancer Center (18) · New Approaches to Neuroblastoma Therapy Consortium (18) · Baylor College of Medicine (12) · Children's Oncology Group (12) · St. Jude Children's Research Hospital (11) · Emory University (6) · National Institutes of Health Clinical Center (CC) (6) · Giselle Sholler (5) · Milton S. Hershey Medical Center (5) · Novartis Pharmaceuticals (5) · Case Comprehensive Cancer Center (3) · City of Hope Medical Center (3) · Dana-Farber Cancer Institute (3) · Fred Hutchinson Cancer Center (3)
United States (239) · Canada (34) · United Kingdom (24) · Australia (19) · France (19) · Germany (16) · Italy (15) · Spain (14) · China (12) · Netherlands (10) · Belgium (5) · Israel (5) · South Korea (5) · Austria (3) · Japan (3)
Giselle Sholler, MD (5) · Kenneth G. Lucas, MD (5) · Shakeel Modak, MD (4) · Steven DuBois, MD (4) · Yizhuo Zhang (4) · Holly Meany, MD (3) · Katherine K. Matthay, MD (3) · Nai-Kong V. Cheung, MD, PhD (3) · Scot C. Remick, MD (3) · AeRang Kim, MD, PhD (2) · Araz Marachelian, MD, MS (2) · Barry J. Maurer, MD, PhD (2) · Brian H. Kushner, MD (2) · Brian Kushner, MD (2)
PMID 31401903, PMID 19171714, PMID 41920422, PMID 11118469, PMID 12091876, PMID 12218188, PMID 14767498, PMID 15033677, PMID 15269160, PMID 1576319, PMID 15814645, PMID 15869455, PMID 15950727, PMID 16234526, PMID 16382236, PMID 1638557, PMID 16421427, PMID 1643631, PMID 16551859, PMID 16849757, PMID 16914576, PMID 17369569, PMID 18048828, PMID 18281544, PMID 18391430, PMID 18470481, PMID 18974373, PMID 19047298, PMID 19075272, PMID 19171709, PMID 19304016, PMID 19430790, PMID 19626208, PMID 19638464, PMID 19805691, PMID 20044751, PMID 20049927, PMID 20145168, PMID 20407240, PMID 20460632, PMID 20570856, PMID 20847174, PMID 20879881, PMID 21074057, PMID 21149662, PMID 21298742, PMID 21343563, PMID 21798350, PMID 21984804, PMID 22010014
P01CA081403 (15), 2023 (5), P30CA008748 (4), U01CA097452 (4), UM1CA097452 (4), P30CA043703 (3), U10CA180886 (3), UM1CA228823 (3), 2017 (2), 2019 (2), P01CA094237 (2), P30CA015704 (2), P30CA033572 (2), U01CA062502 (2), U01CA069856 (2)